


Centre for Biological Engineering		
Document Ref: FSOP048	Issue no v3.1	Issue Date 18-Dec-12

RISK ASSESSMENT REVIEW/REVISION RECORD

Risk Assessment Ref No:	CBE BRA 158 CBE GMO 158	Version Number
		4

This risk assessment should be reviewed **annually** or more frequently if there is any change in the work, or if new information becomes available that indicates the assessment may no longer be valid. **This form should be attached to the front of the current version of the risk assessment or to the new version of the risk assessment if one is issued**

The following review has been carried out on the dates indicated and either the assessment remains valid or it has been amended as indicated.

Name(s) of reviewer: Angharad Elizabeth Evans	Date: 15/07/2019
Signature: 	

Reason for Review:

Risk assessment states that the cell culture and transfection work will be undertaken in H27, the work will be undertaken in H25 instead. Extra safety measures will be implemented as an extra level of precaution for other users of the lab.

There are no changes to the risk assessment, the only change will be the use of a different laboratory to what was originally stated. There will also be no GMO work taking place as part of this risk assessment.


Revision Required (Y/N)	Y
--------------------------------	----------


If Yes, give details of the revision:

As other work will be undertaken in the H25 lab, extra safety measures will be enforced when transfection of cell cultures is underway.

Such measures include:

- Displaying a sign in the entrance of the lab indicating that transfection work is underway and that anyone working in the lab should take precaution
- Changing to a coloured lab coat in second change when the sign is on display
- When transfection is underway a sign will be placed on a single BSC and Incubator indicating that they should not be used, or if they need to be used the operator should do so while understanding the risk.
- An email will be sent to all users of the lab about when the work will commence and the measures that need to be taken during the period when cells are being transfected.

Issued by: P.Hourd	Authorised by: R.I.Temple 	Page 1 of 2
--------------------	--	-------------

Approval:	
<i>Instructions for Reviewer:</i>	
<p>1. The completed form should be forwarded to the CBE Quality Manager. NOTE: Significant revision (See Guidelines GN006 & GN007) will require approval by the person supervising the work and subsequent review and approval by the original approving authority. This may require a revised version of the risk assessment to be issued for re-approval.</p> <p>2. Where an annual review concludes that the risk assessment is still valid ie no revision is required, this should be recorded and the completed form forwarded to the CBE Quality Manager.</p>	
Name of Approver: C. Kavanagh	Date: 16/7/19.
Position: Experimental officer	
Signature: 	
Name of Approver:	Date:
Position:	
Signature:	
Name of Approver:	Date:
Position:	
Signature:	
Name of Approver:	Date:
Position:	
Signature:	